

Tuesday, October 2, 2018

Time	Topic	Speakers
8:30am	Welcome	Cliff Goodman Mark Harris
8:45-10:00	Opening Session: Genetic Medicine in the Context of the US Healthcare System	Carlos Bustamante Howard Levy Larry Van Horn
10:30-11:45	Panel: Defining Real World Value Through Standards & Identification of Key Outcomes A small fraction of the 75,000 genetic tests on the market have sufficient evidence for confident implementation and payment. What is the real-world path to value assessment at scale? What standards are needed to collect the right data? What outcomes are we trying to achieve?	Trent Haywood Kathryn Lang Laurie McGraw
11:45-1:00	Lunch & discussion	
1:00-2:15	Panel: Laboratory and Test Quality, Compared The quality of a lab depends on the test it is performing and the process, technology, data and expertise it has to deliver the result. How can lab quality information be collected, standardized and reported in a way that meets the need of stakeholders?	Julie Eggington Victoria Pratt Kristine Bordenave
2:45-4:00	Panel: Provider Education & Support Most clinicians trained before the human genome was sequenced; even genetics experts need practical support at the point-of-care to deliver high-value genetic medicine. What technical, practical and educational systems can provide this support without overly burdening clinicians?	Emily Edelman Josh Denny Ellen Matloff
4:00-5:00	Investor Perspectives: Trends in genetics and precision medicine at the edge of innovation	Eli Casdin Alex De Winter Nick Naclerio
5:00-5:15	Wrap up / Preview Day 2	Mark Harris
6:00-8:00	Music City at Night – An evening out in Nashville	

Wednesday, October 3, 2018

Time	Topic	Speakers
8:00-8:15	Introduction – Day 2	Mark Harris
8:15-9:30	Panel: Patients and Data Ownership Patients are the center of the Genetic Health Information Network and the end user of the healthcare system. As data is increasingly commoditized, what are our opportunities and obligations?	Dawn Barry James O’Leary Bryce Olson
9:45-11:45	Enabling Genetics & Precision Medicine at Scale Many effective solutions in genetics and precision medicine operate in small pockets. What are the best examples of things that should be scaled, and what are the opportunities (and obstacles) to scale them?	All
12:00-1:00	Closing Discussion: A shared vision for a connected network and next steps - what is success?	Henry Garlich Matt Might Bob Nussbaum

Speakers & Panelists

Trent Haywood, MD, JD

SVP and Chief Medical Officer
Blue Cross Blue Shield Assoc

Carlos Bustamante, PhD

Chair, Department of Biomedical
Data Science
Stanford University

Dawn Barry

Co-founder & President
Luna DNA

Nick Nalcerio, PhD

Founding Partner
Illumina Ventures

Henry Garlich

Dir, Healthcare Value Solutions &
Enhanced Clinical Programs
Blue Shield of California

Howard Levy, MD, PhD

Associate Professor of Medicine
Johns Hopkins Medicine

Kathryn Lang, MD

Global Medical Strategy Head of
Data Science
Pfizer

Laurie McGraw

SVP, Health Solutions
American Medical Association

Victoria Pratt, PhD

President-elect
Assoc for Molecular Pathology

Ellen Matloff, MS, CGC

President & CEO
My Gene Counsel

Eli Casdin

Chief Investment Officer
Casdin Capital

Emily Edelman, MS, CGC

Associate Director of Clinical &
Continuing Education
The Jackson Laboratory

Joshua Denny, MD

Professor, Medicine and Bioinformatics
Vanderbilt University

Bryce Olson

Global Marketing Director, Health & Life
Sciences
Intel

Robert Nussbaum, MD

Chief Medical Officer
Invitae

Matt Might, PhD

Director, Hugh Kaul Personalized
Medicine Institute
Univ. of Alabama at Birmingham

Julie Eggington, MS, PhD

Co-founder & CEO
Ctr for Genomic Interpretation

Alex De Winter, PhD

Managing Director
GE Ventures

Larry Van Horn, PhD

Exec Director, Health Affairs
Owen Graduate School of
Management at Vanderbilt

James O’Leary

Chief Innovation Officer
Genetic Alliance

Kristine Bordenave, MD

Corporate Medical Director
Humana

